Deals With Pfizer, Sanofi-Aventis, AstraZeneca Boost Korea As Clinical Trial Destination
This article was originally published in PharmAsia News
Executive Summary
SEOUL - A string of deals during the past five years with five multinational companies - Pfizer, Sanofi-Aventis, AstraZeneca, Novartis and Japan's Otsuka Pharmaceuticals - have boosted South Korea's status as a leading destination for global clinical trials, according to the government
You may also be interested in...
Korea’s KHIDI, AstraZeneca Ink MOU For Oncology Research
AstraZeneca inks a memorandum of understanding with Korea’s Health Industry Development Institute for oncology research.
Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities
SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said
Merck Signs Wide-Ranging MOU To Help Beef Up Korea's Global R&D Capabilities
SEOUL - Merck & Co. Inc. has signed a memorandum of understanding with South Korea to invest KRW 210 billion ($192.9 million) in the country for research and development of new drugs, including manpower exchanges, Korea's Ministry of Health and Welfare said